美国脂肪酸类产品监管比较研究

• 管理研究 • 下一篇

美国脂肪酸类产品监管比较研究

李昕烨,杨悦

沈阳药科大学工商管理学院；东北制药集团沈阳第一制药有限公司,沈阳药科大学工商管理学院

收稿日期:2017-10-20 修回日期:2017-11-11 出版日期:2017-12-25 发布日期:2017-12-25

A Comparative Study on the Regulation of Fatty Acid Products in the United States

lixinye and

Shenyang pharmaceutical university institute of business administration；Northeast Pharmaceuticals Group Shenyang NO.1 Pharmaceutical Co.Ltd,,

Received:2017-10-20 Revised:2017-11-11 Online:2017-12-25 Published:2017-12-25

摘要/Abstract

摘要： 目的：本文以美国脂肪酸类产品(药品与保健食品)为例,对二者定义、上市前监管、标签标注、上市后监管进行介绍以及比较研究,为我国即注册成药品又注册成保健食品的同种物质的监管提供借鉴。方法；运用文献研究方法与比较研究方法对美国脂肪酸类产品定义、上市前监管、标签标注、上市后监管进行介绍以及比较研究。结论：我国应对药品与保健食品定义加以明确界定；我国保健食品监管模式应从全程监管向风险控制过渡；我国应对保健食品限制声称以及统一保健品含量标识。

Abstract: Objective: This paper compared the definition, pre-market supervision, labeling, post-marketing supervision of the fatty acid drugs and the fatty acids dietary supplements in the United States, and to provide reference for the regulation on the same substance that is registered as a drug but also registered as health food in our country. Methods: The literature research methods and comparative research methods were used to introduce and compare the definition, pre-market supervision, label labeling and post-market supervision of fatty acid products in the United States. Conclusion: our country should deal with the definition of drugs and health food to be clearly defined; our country"s health food regulatory model should be translate the whole regulatory into the risk control transition; our country should restrict the health claims and unified the content of the health food

李昕烨,杨悦. 美国脂肪酸类产品监管比较研究[J]. .

lixinye and. A Comparative Study on the Regulation of Fatty Acid Products in the United States[J]. .

参考文献

[1]耿莉萍.当前我国保健食品市场存在的问题与监管对策[J].食品科学技术学报,2013,31(3):7-9.
[2]陈文,魏涛,秦菲,金宗濂.美国对功能食品的管理[J].食品工业科技.2009,07(30):297.
[3] Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). [EB/OL].https://www.ncbi.nlm.nih.gov/books/NBK209320/. 2017-04-21.
[4] Daniel Hilleman, Aiman Smer.Prescription Omega-3 Fatty Acid Products and Dietary Supplements Are Not Interchangeable[J].Managed Care. 2016,25(1):46-52.
[5] Federal Food, Drug,and Cosmetic Act, FD C Act SEC.201.(g)(1). [EB/OL].https://www.fda.gov/regulatoryinformation/lawsenforcedbyfda/federalfooddrugandcosmeticactfdcact/default.htm. 2017-04-21.
[6] Federal Food, Drug,and Cosmetic Act FD C Act SEC.201(ff)(1)(2). [EB/OL].https://www.fda.gov/regulatoryinformation/lawsenforcedbyfda/federalfooddrugandcosmeticactfdcact/default.htm. 2017-04-21.
[7] Federal Food, Drug,and Cosmetic Act FD C Act SEC.201(ff)(3). [EB/OL].https://www.fda.gov/regulatoryinformation/lawsenforcedbyfda/federalfooddrugandcosmeticactfdcact/default.htm. 2017-04-21.
[8] Drugs vs. Supplements: What’s the Difference? [EB/OL].https://drugabuse.com/drugs-vs-supplements-whats-the-difference/.2017-05.04.
[9]Dietary Supplements:What Is Safe? [EB/OL].https://www.cancer.org/treatment/treatments-and-side-effects/complementary-and-alternative-medicine/dietary-supplements.html. 2017-05-01
[10] 兰洁,王谨瑾,王森,杨明. 国际保健品管理的比较研究[J].亚太传统医药.2008,4(7):4.
[11] PRESCRIBING INFORMATION, LOVAZA?.[EB/OL].https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021654s023lbl.pdf.2017-05-03.
[12] John Hathcock. Dietary Supplements: How They Are Used and Regulated[J]. The Journal of Nutrition.2001,131(3):11145-11175.
[13] The Society for Food Science and Technology. Dietary Supplements:Nutritional and Legal Considerations[J]. Food Technology.1999,53(7):87-95.
[14] 赵丹宇,张志强.国内外保健食品管理法规标准比较研究[J]. 中国食品卫生杂志.2004,16(5):404-407.
[15] 食品标签指南. [EB/OL].http://www.fda.gov/downloads/Food/GuidanceRegulation/UCM254432.pdf.2009-10-01.